{"doi":"10.1016/j.msard.2021.103179","title":"Natalizumab subcutaneous injection for the treatment of relapsing multiple sclerosis patients: A new delivery route","abstract":null,"journal":"Multiple Sclerosis and Related Disorders","year":2021,"id":623590,"datarank":0.5239400285869251,"base_score":1.9459101490553132,"endowment":1.9459101490553132,"self_citation_contribution":0.29188652235829704,"citation_network_contribution":0.23205350622862814,"self_endowment_contribution":0.29188652235829704,"citer_contribution":0.23205350622862814,"corpus_percentile":null,"corpus_rank":null,"citation_count":6,"citer_count":6,"citers_with_citation_signal":6,"citers_with_endowment":6,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1611657,"name":"Ricardo Alonso","orcid":null,"position":1,"is_corresponding":false},{"id":1611658,"name":"Berenice Silva","orcid":null,"position":2,"is_corresponding":false},{"id":1062739,"name":"Edgar Carnero Contentti","orcid":"0000-0001-7435-5726","position":3,"is_corresponding":false},{"id":1062744,"name":"Pablo A. López","orcid":"0000-0002-7705-095X","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Natalizumab subcutaneous injection for the treatment of relapsing multiple sclerosis patients: A new delivery route","abstract":null,"is_dataset_classified":null,"base_score":1.9459101490553132,"endowment":1.9459101490553132,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"34339931","pmcid":null,"openalex_id":"https://openalex.org/W3183153902","authors":[],"funders":[],"total_grants":0,"fwci":0.8534,"citation_percentile":0.70998415,"influential_citations":0,"citation_trend":[{"year":2022,"count":1},{"year":2023,"count":4},{"year":2024,"count":1}],"oa_status":"closed","license":"https://doi.org/10.15223/policy-004","oa_locations":[{"url":"https://api.elsevier.com/content/article/PII:S2211034821004466?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S2211034821004466?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.msard.2021.103179","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/34339931","host_type":"repository"}],"fields_of_study":["Multiple Sclerosis Research Studies","Polyomavirus and related diseases","Peripheral Neuropathies and Disorders","Humans","Immunologic Factors","Injections, Subcutaneous","Interferon-beta","Multiple Sclerosis","Multiple Sclerosis, Relapsing-Remitting","Natalizumab"],"mesh_terms":["Natalizumab","Humans","Immunologic Factors","Injections, Subcutaneous","Multiple Sclerosis","Interferon-beta","Multiple Sclerosis, Relapsing-Remitting"],"keywords":["Natalizumab","Medicine","Multiple sclerosis","Subcutaneous injection","Fingolimod","Dermatology","Immunology","Internal medicine"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-04T00:28:27.246270Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}